Inventor · disambiguated record
David Y. Jackson
Also filed as: JACKSON DAVID · JACKSON DAVID Y · JACKSON DAVID YOUNG
19 granted patents·26 pending applications·172 citations·filing 1988–2022
93Inventor score
Files withGENENTECH INC16BOLT BIOTHERAPEUTICS INC7MAGENTA THERAPEUTICS INC4UNIV LELAND STANFORD JUNIOR4IGENICA BIOTHERAPEUTICS INC3
Top patents by PatentIndex Score
45 records- 0195US7947839B2Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of useGENENTECH INC·Filed 2006·Granted May 24, 2011·53 cites·16 claims
- 0292US11110178B2Antibody adjuvant conjugatesUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Sep 7, 2021·3 cites·30 claims
- 0391US10675358B2Antibody adjuvant conjugatesUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Jun 9, 2020·5 cites·30 claims
- 0490US6469047B1Tyrosine derivativesGENENTECH INC·Filed 2000·Granted Oct 22, 2002·43 cites·18 claims
- 0585US11229711B2Linkers for antibody-drug conjugates and related compounds, compositions, and methods of useMAGENTA THERAPEUTICS INC·Filed 2014·Granted Jan 25, 2022·3 cites·5 claims
- 0684US10781259B2Modified antibodies and related compounds, compositions, and methods of useMAGENTA THERAPEUTICS INC·Filed 2014·Granted Sep 22, 2020·3 cites·29 claims
- 0779US6933314B2Integrin receptor inhibitorsGENENTECH INC·Filed 2003·Granted Aug 23, 2005·9 cites·11 claims
- 0877US6706753B2Integrin receptor inhibitorsGENENTECH INC·Filed 2002·Granted Mar 16, 2004·7 cites·10 claims
- 0977US6265572B1Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agentsHOFFMANN LA ROCHE·Filed 2000·Granted Jul 24, 2001·10 cites·26 claims
- 1076US5629173AMethods of use of serine protease variants having peptide ligase activityGENENTECH INC·Filed 1995·Granted May 13, 1997·34 cites·27 claims
- 1175US2023111340A1Antibody adjuvant conjugatesUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 1274US11547761B1Antibody adjuvant conjugatesUNIV LELAND STANFORD JUNIOR·Filed 2021·Granted Jan 10, 2023·0 cites·91 claims
- 1368US11400164B2Immunoconjugates targeting HER2BOLT BIOTHERAPEUTICS INC·Filed 2021·Granted Aug 2, 2022·0 cites·44 claims
- 1467US2020392108A1Antibody-drug conjugates and related compounds, compositions and methodsMAGENTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1566US2023109312A1Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of useMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1666US2022347311A1Immunoconjugates Targeting HER2BOLT BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1764US2009325962A1Tyrosine derivativeGENENTECH INC·Filed 2009·Application pending·0 cites
- 1862US2014363454A1Antibody-Drug Conjugates, Compositions and Methods of UseIGENICA BIOTHERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 1962US2003129675A1Assay methodGENENTECH INC·Filed 2002·Application pending·0 cites
- 2062US2020108151A1Antibody adjuvant conjugatesBOLT BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2162US2013224228A1Antibody-Drug Conjugates and Related Compounds, Compositions, and MethodsIGENICA INC·Filed 2012·Application pending·0 cites
- 2260US2009136537A1Lipopeptide compositions and methods of use therofEVANS ROBERT·Filed 2008·Application pending·0 cites
- 2359US11932695B2Modified antibodies and related compounds, compositions and methods of useSENSEI BIOTHERAPEUTICS INC·Filed 2020·Granted Mar 19, 2024·0 cites·6 claims
- 2457US7265146B2Integrin receptor inhibitorsGENENTECH INC·Filed 2005·Granted Sep 4, 2007·0 cites·17 claims
- 2557US2019015516A1Antibody adjuvant conjugatesBOLT BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2656US2006234306A1Assay methodGENENTECH INC·Filed 2006·Application pending·0 cites
- 2755US2009226465A1Macrocyclic depsipeptide antibody-drug conjugates and methodsJACKSON DAVID Y·Filed 2006·Application pending·0 cites
- 2855US2018147294A1Antibody-drug conjugates, compositions and methods of useJACKSON DAVID Y·Filed 2017·Application pending·0 cites
- 2954US7595399B2Tyrosine derivativesGENENTECH INC·Filed 2004·Granted Sep 29, 2009·0 cites·20 claims
- 3054US2005233387A1Assay methodGENENTECH INC·Filed 2005·Application pending·0 cites
- 3154US2016303247A1Antibody-Drug Conjugates and Related Compounds, Compositions, and MethodsIGENICA BIOTHERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 3253US7166600B2Thiocarbamate inhibitors of alpha-4 integrinsGENENTECH INC·Filed 2006·Granted Jan 23, 2007·0 cites·20 claims
- 3353US7015323B2Thiocarbamate inhibitors of alpha-4 integrinsGENENTECH INC·Filed 2004·Granted Mar 21, 2006·0 cites·18 claims
- 3451US2015231240A1Anti-c16orf54 antibodies and methods of use thereofIGENICA INC·Filed 2013·Application pending·0 cites
- 3551US2002035104A1Integrin receptor inhibitorsGENENTECH INC·Filed 2001·Application pending·0 cites
- 3650US2004110753A1Tyrosine derivativesGENENTECH INC·Filed 2002·Application pending·0 cites
- 3747US2002004247A1Assay methodGENENTECH INC·Filed 2000·Application pending·0 cites
- 3846US2007134243A1Antibody drug conjugates and methodsGAZZARD LEWIS J·Filed 2005·Application pending·0 cites
- 3946US2021187115A1Immunoconjugates Targeting EGFRBOLT BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4045US4916238AProcess for preparing allenic prostanoic acid derivativesSYNTEX INC·Filed 1988·Granted Apr 10, 1990·2 cites·18 claims
- 4145US2021154316A1ImmunoconjugatesBOLT BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4240US2023270067A1Heterozygous cenh3 monocots and methods of use thereof for haploid induction and simultaneous genome editingUNIV GEORGIA·Filed 2021·Application pending·0 cites
- 4339US2021284750A1Immunoconjugate Synthesis MethodBOLT BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4438US2019209704A1Novel antibody-drug conjugates and related compounds, compositions and methods of useIGENICA BIOTHERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 4529US5248788AProcess for preparing allenic prostanoic acid derivativesSYNTEX INC·Filed 1990·Granted Sep 28, 1993·0 cites·10 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →